Enveric Enters into Clinical Stage Development of Lead Asset, EV101, in Israel with MOH Approval NAPLES, Fla., July 8, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing…
Read More
https://www.youtube.com/watch?v=CDlMQVwiQNI
Read More
https://news.bloomberglaw.com/pharma-and-life-sciences/texas-the-latest-state-to-legalize-psychedelic-medical-research
Read More
https://www.youtube.com/watch?v=SENBJHkK0KE
Read More
https://www.benzinga.com/markets/cannabis/21/06/21433528/exclusive-magicmed-ceo-on-psychedelics-companys-secret-sauce-m-a-deal-with-enveric-biosciences
Read More
NAPLES, Fla., June 3, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel naturally occurring medicines to improve quality of life for cancer patients, and MagicMed Industries (“MagicMed”),…
Read More
https://www.benzinga.com/markets/cannabis/21/05/21345081/psyched-nasdaq-gets-its-third-psychedelics-company-mynd-goes-public-delic-buys-new-research-faci
Read More
With this acquisition, Enveric will expand and complement its pipeline of naturally occurring cannabinoid compounds with a robust portfolio of psychedelic-derived molecules Enveric aims to move into the clinic with…
Read More
https://www.benzinga.com/markets/cannabis/21/05/21261079/another-psychedelics-company-joins-exclusive-nasdaq-group-with-enverics-acquisition-of-magicmed-
Read More
